Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 4
2(40.0%)
Phase 3
2(40.0%)
Phase 2
1(20.0%)
5Total
Phase 4(2)
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06650488Phase 4Recruiting

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

Role: lead

NCT06637332Phase 4Recruiting

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Role: lead

NCT04851015Phase 3Recruiting

Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

Role: lead

NCT04886284Phase 2Recruiting

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Role: lead

NCT07253688Phase 3Recruiting

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

Role: lead

All 5 trials loaded